When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab-Reference-Cited by-同舟云学术

When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab

Published:2016-01-06 Issue:6 Volume:63 Page:962-963
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Adamson Peter C.¹,Park Julie R.²,Pearson Andrew D.³⁴

Affiliation:

1. Children's Oncology Group, The Children's Hospital of Philadelphia; Philadelphia Pennsylvania

2. Division of Pediatric Hematology and Oncology; Seattle Children's Hospital/University of Washington; Seattle Washington

3. Formerly, Division of Clinical Studies; The Institute of Cancer Research; London UK

4. Formerly, Paediatric Drug Development; Children and Young People's Unit; The Royal Marsden NHS Foundation Trust; Sutton UK

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.25891/fullpdf

Reference8 articles.

1. http://www.nice.org.uk/guidance/GID-TAG507/documents/appraisal-consultation-document

2. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study;Matthay;J Clin Oncol,2009

3. Children's Oncology Group's 2013 blueprint for research: Neuroblastoma;Park;Pediatr Blood Cancer,2013

4. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial;Pearson;Lancet Oncol,2008

5. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma;Yu;N Engl J Med,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Market access to new anticancer medicines for children and adolescents with cancer in Europe;European Journal of Cancer;2022-04

2. When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma;Journal of Clinical Oncology;2022-01-10

3. Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group;Cancer;2021-10-08

4. Asparaginase products in upfront acute lymphoblastic leukemia therapy: Value, location, and style;Pediatric Blood & Cancer;2018-10-14

5. Dinutuximab for the treatment of pediatric patients with neuroblastoma;Drugs of Today;2017